Capsule endoscopy findings for the diagnosis of Crohn's disease: a nationwide case-control study.

"Conflict of interest Motohiro Esaki received research grants from, Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., AbbVie GK, ZERIA Pharmaceutical Co., Ltd., and Asahi Kasei Medical Co., Ltd., and lecture fee from Mitsubishi Tanabe Pharma Corporation and AbbVie GK, outside the submitted work. Takayuki Matsumoto received research grants from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., and Nippon Kayaku Co., Ltd., and lecture fee from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., KYORIN Pharmaceutical Co., Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Pfizer Inc., Zeria Pharmaceutical Co., Ltd., and AstraZeneca plc, and advisory fee from JIMRO Co., Ltd., Kissei Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., outside the submitted work. Naoki Ohmiya received research grants from Otsuka Pharamaceutical Factory, Inc., JIMRO Co., Ltd., Mochida Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Astellas Pharma Inc., Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., TAIHO Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co., Ltd., Tsumura & Co., KYORIN Pharmaceutical Co., Ltd., and Asahi kasei Pharma, and lecture fee from KYORIN Pharmaceutical Co., Ltd., Fujifilm medical Co., Covidien Japan, EA Pharma Co. Ltd., KYORIN Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., ZERIA Pharmaceutical Co., Ltd., Astellas Pharma Inc., AbbVie GK, and Mylan Inc, outside the submitted work. Kenji Watanabe received research grants from AbbVie GK, Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., Asahi Kasei Medical Co., Ltd., Kyowa Hakko Kirin Co., Ltd, Kyorin Pharmaceutical Co., Ltd, Astellas Pharma Inc, and JIMRO Co., Ltd., and consulting fee from EA Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Kyorin Pharmaceutical Co., Ltd., Asahi Kasei Medical Co. Ltd., Kyowa Hakko Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Olympus Corporation, Covidien Japan Co., Ltd., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., and Otsuka Pharmaceutical Co., Ltd., and lecture fee from Mitsubishi Tanabe Pharma Corporation, Eisai Co., Ltd, AbbVie GK, Asahi Kasei Medical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Astellas Pharma Inc., JIMRO Co., Ltd., UCB Japan Co., Ltd., Zeria Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Olympus Corporation, Covidien Japan Co., Ltd., and Otsuka Pharmaceutical Co., Ltd., and advisory fee from Takeda Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., EA Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and JIMRO Co., Ltd., outside the submitted work. Fumihito Hirai received research grants from AbbVie GK, Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., JIMRO Co., Ltd., ZERIA Pharmaceutical Co., Ltd., and Eisai Co., Ltd., and lecture fee from AbbVie GK, EA Pharma Co., Ltd., Eisai Co., Ltd. And Mitsubishi Tanabe Pharma Corporation, outside the submitted work. Atsushi Hirano received research grants from AbbVie GK, and Mitsubishi Tanabe Pharma Corporation, outside the submitted work. Takanari Kitazono received research grants from Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co. Ltd., MSD Co., Ltd. Nippon Boehringer Ingelheim Co., Ltd., Sanofi-Aventis Co., Ltd. Pfizer Inc., Bayer yakuhin, Ltd., and Eisai Co., Ltd., and lecture fee from Daiichi Sankyo Co., Ltd., Bayer yakuhin, Ltd., and Chugai Pharmaceutical Co., Ltd., outside the submitted work. Mamoru Watanabe received research grants from Asahi Kasei Medical Co., Ltd., Ajinomoto Co., Inc., AbbVie GK, EA Pharma Co., Ltd., Eisai Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Otsuka Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co. Ltd., Zeria Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Mochida Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Astellas Pharma Inc., MSD K.K., Dainippon Sumitomo Dainippon Pharma Co., Ltd., Bristol-Myers, K.K, and Chugai Pharmaceutical Co., Ltd., and lecture fees from Mitsubishi Tanabe Pharma Corp., Eisai Co., Ltd., Kyorin Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Ajinomoto Co., Inc., AbbVie GK, Takeda Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co. Ltd., Zeria Pharmaceutical Co., Ltd., Asahi Kasei Medical Co., Ltd., EA Pharma Co., Ltd., Astellas Pharma Inc., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical Co., Ltd., Gilead Sciences, Inc., Celgene Corp., outside the submitted work. Toshiyuki Matsui received research grants from AbbVie GK, Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., JIMRO Co., Ltd., ZERIA Pharmaceutical Co., Ltd., Eisai Co., Ltd., Astellas Pharma Inc, and Takeda Pharmaceutical Co. Ltd., and lecture fee from AbbVie GK, and EA Pharma Co., outside the submitted work. Yasuo Suzuki received research grants from AbbVie GK, Mitsubishi Tanabe Pharma Corporation, Ltd., EA Pharma Co., Ltd., JIMRO Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Nippon Kayaku Co., Ltd., and lecture fee from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, EA Pharma Co. Ltd., ZERIA Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and KYORIN Pharmaceutical Co., Ltd., outside the submitted work. All other authors have no competing interests to declare."

"Funding This work was supported in part by Health and Labour Sciences Grants for research on intractable diseases from Ministry of Health, Labour and Welfare of Japan (Investigation and Research for Intractable Inflammatory Bowel Disease). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report."